Evidence map›Paper›PMID 24051419›Full record

Trial reportJournal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society2013

Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.

Kimberly M Winges, John S Werner, Danielle J Harvey, Kimberly E Cello, Mary K Durbin, Laura J Balcer, Peter A Calabresi, John L Keltner

Open access · greenAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Fingolimod for relapsing-remitting multiple sclerosis.The Cochrane database of systematic reviews · 2016
    Pooled it
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Review
  12. Optical coherence tomography for retinal imaging in multiple sclerosis.Degenerative neurological and neuromuscular disease · 2014
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Kimberly M WingesDepartment of Ophthalmology (KMW), Veterans Administration Medical Center, Portland, Oregon; Department of Ophthalmology and Vision Science (KMW, JSW, KEC, JLK), Division of Biostatistics (DJH), Department of Public Health Sciences, and Departments of Neurology and Neurosurgery (JLK), University of California Davis School of Medicine, Davis, California; Carl Zeiss Meditec, Inc (MKD), Dublin, California; Department of Neurology (LJB), New York University Langone Medical Center, New York, New York; and Department of Neurology (PAC), Johns Hopkins University School of Medicine, Baltimore, Maryland.
John S Werner
Danielle J Harvey
Kimberly E Cello
Mary K Durbin
Laura J Balcer
Peter A Calabresi
John L Keltner
Johns Hopkins Medicine · USJohns Hopkins University · USNYU Langone Health · USCarl Zeiss (United States) · USUniversity of California, Davis · US

Funding

OPTICAL &NEURAL CHANGES IN THE AGING VISUAL SYSTEMR01AG004058 · NIA · UNIVERSITY OF COLORADO AT BOULDER · PI WERNER, JOHN S · 1988 to 2015
$1.9M
NIA NIH HHS R01 AG004058
6 · The paper itself

Abstract

backgroundPatients with multiple sclerosis (MS) demonstrate thinning of peripapillary retinal nerve fiber layer (RNFL) and decreased macular volume as measured by optical coherence tomography (OCT). To our knowledge, there are no previous reports from a large MS OCT database with strict quality control measures that quantitate RNFL and macula in patients with relapsing-remitting multiple sclerosis.

methodsThe University of California Davis OCT Reading Center gathered OCT data at baseline as part of the North American phase 3 trial of fingolimod (Gilenya). Average RNFL thickness (RNFLT) and macular volume (TMV) were measured using time domain OCT (TD-OCT). RNFL quadrants, clock hours, and macular subfields were included. With strict quality control and accounting for signal strength differences, scans were categorized as "reduced" or "not reduced" for each field, based on being less than 5th percentile for age-matched controls derived from the normative database in the scanner software. Patients were deemed "abnormal" if at least 1 eye had reduced values for a given parameter. Patients with abnormalities in corresponding RNFL and macular subfields were compared by cross-tabulation.

resultsThe TD-OCT data were prospectively collected from 939 of the 1,083 trial patients, 712 of whom met all final quality and data inclusion criteria. Of the final cohort, 242 (34.0%) demonstrated reduced (less than 5th percentile) average RNFLT in at least 1 eye. One hundred seventy-eight (25.0%) patients had reduced TMV. One hundred twenty-eight (18.0%) demonstrated both reduced TMV and RNFLT in the same eye, whereas 42 (5.8%) had reduced TMV and RNFLT in both eyes. Of the 242 patients with reduced average RNFL thickness, 128 (52.9%) also had reduced TMV. Fifty patients had reduced TMV in the absence of reduced RNFLT in at least 1 eye, a cohort prevalence of 7.0%. Quadrant and subfield analysis showed a predominance of temporal and inferior RNFL thinning, with inferior macular thinning corresponding best to RNFL thinning.

conclusionRNFL and macular thinning/volume loss is common at baseline in relapsing-remitting multiple sclerosis, as measured by TD-OCT. When the RNFL is thin, the macular volume is reduced in more than half of the patients. There is a population of reduced TMV without any reduction in RNFLT. Documenting the prevalence and distribution of these structural abnormalities supports recent reports and suggests new retinal areas to probe for functional vision changes in MS.

Indexed as

Tomography, Optical CoherenceAdolescentAdultFemaleFingolimod HydrochlorideHumansImmunosuppressive AgentsMacula LuteaMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingNerve FibersNorth AmericaPropylene GlycolsRetinaRetrospective StudiesFingolimod HydrochlorideImmunosuppressive AgentsPropylene GlycolsSphingosine

Identifiers

PMID24051419
PMCPMC3959779
OpenAlexW2038252368

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.